MedTrace Logo

Determination of Drug Levels for Pharmacotherapy of Heart Failure

NCT06035978 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-01-18

No results posted yet for this study

Summary

The aim of this study is to determine whether and how serum concentrations of the used medicinal products, including their metabolites, correlate with selected clinical indicators of heart failure (NT-proBNP concentration, 6-minute walk test, quality of life questionnaire, echocardiographic parameters, hospitalization for HFrEF, length of survival).

Conditions

Interventions

DRUG

Nebivolol

Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

DRUG

Valsartan and Sacubitril

Valsartan and Sacubitril (Entresto) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

DRUG

Carvedilol

Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

DRUG

Bisoprolol

Bisoprolol (Concor) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

DRUG

Metoprolol

Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

DRUG

Spironolactone

Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

Sponsors & Collaborators

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Marie Lazárová, MD, Ph.D. · University Hospital Ostrava

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-31
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06035978 on ClinicalTrials.gov